EQS-News
CHEPLAPHARM closes financial year 2023 with record revenue and double-digit growth
- Record revenue: €1,498.4 million, +17% YoY growth
- EBITDA: €780.5 million, +14% YoY increase
- New affiliates in Japan and Switzerland, international expansion
EQS-News: Cheplapharm AG / Key word(s): Annual Results/Annual Report
CHEPLAPHARM CLOSES FINANCIAL YEAR 2023 WITH RECORD REVENUE AND DOUBLE-DIGIT GROWTH |
- Double-digit revenue growth again: +17% YoY to € 1,498.4 million (FY2022: € 1,279.5 million)
- EBITDA increases significantly by +14% YoY to € 780.5 million (FY2022: € 685.7 million)
- EBITDA margin remains at a high and industry-leading level of 52% (FY2022: 54%)
- New affiliates in Japan and Switzerland drive transformation into an international group of companies
- Number of employees grows to 666, an increase of 24% (FY2022: 535)
The CHEPLAPHARM Group, a global leader in the acquisition of originator products from the research-based pharmaceutical industry, closed the financial year 2023 with a record revenue of € 1,498.4 million. The company, headquartered in Greifswald/Germany, is continuing its dynamic and profitable double-digit percentage growth track. In addition to the revenue record, the opening of the affiliates in Japan and Switzerland are important milestones in the transformation to an international group of companies. The largest transaction in the company's history, the acquisition of the Zyprexa portfolio from Eli Lilly for a purchase price of around € 1.3 billion, rounds off the successful financial year 2023.
The annual financial statements for the financial year 2023 published today show a year-over-year increase in revenue of +17% to € 1,498.4 million (FY2022: € 1,279.5 million). EBITDA totalled € 780.5 million in the reporting period, an increase of +14% compared to the financial year 2022 (FY2020: € 685.7 million). At 52%, the EBITDA margin remained at a high and industry-leading level in 2023. CHEPLAPHARM is thus continuing its dynamic and profitable growth track over the last years in 2023 as well and significantly exceeding the targets it has set itself.